Cutting-edge tech for cancer, HIV, TB therapeutics
BioNTech focuses on combining groundbreaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and other serious diseases. The foundation works with BioNTech on developing preclinical vaccines and immunotherapy candidates to prevent HIV and TB infection, working toward durable antiretroviral therapy-free remission of HIV disease.
- Focus areas
- Life Sciences
- Investment type
- Direct equity
- Status
- Active
- Initial investment
- Series C
- Partnered in
- 2019
- Headquarters
- Germany
More about our work
Our focus
We embrace science and technology innovations that solve old problems in new ways, challenge status quos, and build on past breakthroughs. Our six domains of focus comprise 40+ program strategies across the foundation’s nearly $9B annual charitable support.
Investment Approach
How the Strategic Investment Fund is fostering partnerships with the private sector to leverage the globe’s most groundbreaking global innovations for societal good.
Our Team
The SIF Investment Committee brings depth of experience to global investment programs, with a proven track record of innovation across sectors and scale.